The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Melissa Johnson named program director of lung cancer research at Sarah Cannon

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Melissa Johnson was named program director of lung cancer research at Sarah Cannon.

In this role, Johnson will lead the lung cancer clinical trial portfolio across the Sarah Cannon network.

Since joining Sarah Cannon in 2014, Johnson has served as the associate director of lung cancer research at Sarah Cannon Research Institute, supporting the growth of early phase compounds in thoracic malignancies.

Johnson will continue to work in early phase drug development as well as lead the Solid Tumor Immune Effector Cellular Therapy Program at Sarah Cannon. She is also the chair of the Cancer Committee at TriStar Centennial Medical Center in Nashville.

Johnson begins her position in January at Sarah Cannon headquarters in Nashville. She will continue to care for patients as a partner with Tennessee Oncology, PLLC.

Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
By Claire Marie Porter
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account